Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew D Galbraith

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Medrxiv : the Preprint Server for Health Sciences|December 17, 2020
Seroconversion stages COVID19 into distinct pathophysiological statesMatthew D Galbraith, Kohl T Kinning, Kelly D Sullivan, et al.
Elife|March 16, 2021
Seroconversion stages COVID19 into distinct pathophysiological statesMatthew D Galbraith, Kohl T Kinning, Kelly D Sullivan, et al.
The Journal of Allergy and Clinical Immunology|August 29, 2024
Metabolic dysfunction mediated by HIF-1α contributes to epithelial differentiation defects in eosinophilic esophagitisSinéad Ryan, Louise Crowe, Sofía N Almeida Cruz, et al.
Nature Metabolism|November 13, 2023
Inhibition of the proline metabolism rate-limiting enzyme P5CS allows proliferation of glutamine-restricted cancer cellsSamantha J Linder, Tiziano Bernasocchi, Bárbara Martínez-Pastor, et al.
Neuro-Oncology|July 24, 2023
EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progressionArthur R Wolin, Melanie Y Vincent, Taylor Hotz, et al.
Elife|December 31, 2024
JAK inhibition decreases the autoimmune burden in Down syndromeAngela L Rachubinski, Elizabeth Wallace, Emily Gurnee, et al.
Medrxiv : the Preprint Server for Health Sciences|March 24, 2021
The COVIDome Explorer Researcher PortalKelly D Sullivan, Matthew D Galbraith, Kohl T Kinning, et al.
Cell Reports|November 14, 2019
Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down SyndromeKatherine A Waugh, Paula Araya, Ahwan Pandey, et al.
Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
JAK inhibition decreases the autoimmune burden in Down syndromeAngela L Rachubinski, Elizabeth Wallace, Emily Gurnee, et al.
Cancer Research|April 29, 2020
Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and MetastasisHengbo Zhou, Melanie A Blevins, Jessica Y Hsu, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Medrxiv : the Preprint Server for Health Sciences|December 17, 2020
Seroconversion stages COVID19 into distinct pathophysiological statesMatthew D Galbraith, Kohl T Kinning, Kelly D Sullivan, et al.
Elife|March 16, 2021
Seroconversion stages COVID19 into distinct pathophysiological statesMatthew D Galbraith, Kohl T Kinning, Kelly D Sullivan, et al.
The Journal of Allergy and Clinical Immunology|August 29, 2024
Metabolic dysfunction mediated by HIF-1α contributes to epithelial differentiation defects in eosinophilic esophagitisSinéad Ryan, Louise Crowe, Sofía N Almeida Cruz, et al.
Nature Metabolism|November 13, 2023
Inhibition of the proline metabolism rate-limiting enzyme P5CS allows proliferation of glutamine-restricted cancer cellsSamantha J Linder, Tiziano Bernasocchi, Bárbara Martínez-Pastor, et al.
Neuro-Oncology|July 24, 2023
EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progressionArthur R Wolin, Melanie Y Vincent, Taylor Hotz, et al.
Elife|December 31, 2024
JAK inhibition decreases the autoimmune burden in Down syndromeAngela L Rachubinski, Elizabeth Wallace, Emily Gurnee, et al.
Medrxiv : the Preprint Server for Health Sciences|March 24, 2021
The COVIDome Explorer Researcher PortalKelly D Sullivan, Matthew D Galbraith, Kohl T Kinning, et al.
Cell Reports|November 14, 2019
Mass Cytometry Reveals Global Immune Remodeling with Multi-lineage Hypersensitivity to Type I Interferon in Down SyndromeKatherine A Waugh, Paula Araya, Ahwan Pandey, et al.
Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
JAK inhibition decreases the autoimmune burden in Down syndromeAngela L Rachubinski, Elizabeth Wallace, Emily Gurnee, et al.
Cancer Research|April 29, 2020
Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and MetastasisHengbo Zhou, Melanie A Blevins, Jessica Y Hsu, et al.
Pageof 7